That window lets the gel form in your stomach so the first bite meets a half-full tank
FDA labeling for GLP-1 medications approved for chronic weight management, along with major clinical guidelines, generally describes candidates as adults with a BMI of 30 or higher, or a BMI of 27 or higher when accompanied by at least one weight-related health condition such as high blood pressure, type 2 diabetes, or abnormal cholesterol levels
While binding to GLP-1 causes pancreatic cells to secrete insulin, in the brain, GLP-1 activates neurons in the hypothalamus, resulting in a feeling of satiation, or fullness
At the same time, the brain fights that effort
It is anticipated that oxidative stress and antioxidants will continue to garner the interest of numerous researchers for years to come